Details of the Drug Pharmacogenomic Perturbation Atlas

Doxylamine Drug Info

Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline

Therapeutic Class

Hypnotics and Sedatives

Cross-matching ID

PubChem CID

3162

ChEBI ID

CHEMBL1004

CAS Number

CAS 469-21-6

TTD Drug ID

D0Y2LR

ACDINA Drug ID

D00216

General Information of Drug (ID: DMKOXFE)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Long-term depression	1.89	1.95e-2	55/60 (91.67%)	LYN;GNAS;GNAQ;...
DNA replication	1.88	9.74e-3	34/36 (94.44%)	DNA2;POLE2;RFC3;...
Oocyte meiosis	1.85	1.62e-2	90/129 (69.77%)	SMC1A;CALML5;FBXO5;...
Proteasome	1.84	1.46e-2	44/46 (95.65%)	PSMA6;PSMA3;PSME2;...
Fanconi anemia pathway	1.82	1.36e-2	36/54 (66.67%)	RAD51;RAD51C;CENPX;...
Homologous recombination	1.82	1.14e-2	35/41 (85.37%)	RAD51;RAD51C;BRIP1;...
Cell cycle	1.80	1.11e-2	110/124 (88.71%)	SMC1A;CHEK1;E2F5;...
Mismatch repair	1.77	1.34e-2	22/23 (95.65%)	MSH2;RFC3;MSH6;...
Progesterone-mediated oocyte maturation	1.71	3.79e-2	75/100 (75%)	CCNA2;CCNB2;BUB1;...
Selenocompound metabolism	1.70	3.70e-2	11/17 (64.71%)	PAPSS2;SEPHS1;KYAT3;...
One carbon pool by folate	1.68	4.07e-2	15/20 (75%)	MTHFD1;ATIC;TYMS;...
Basal transcription factors	1.67	4.63e-2	37/45 (82.22%)	MNAT1;TAF9B;TAF5;...
Parkinson disease	1.65	4.65e-2	176/249 (70.68%)	GNAS;TUBA1A;CALML5;...
Wnt signaling pathway	1.65	4.80e-2	124/166 (74.7%)	DAAM1;LGR5;NFATC3;...
Protein processing in endoplasmic reticulum	-1.81	3.85e-2	127/171 (74.27%)	SEC24A;SEC31B;HSPA1A;...
Complement and coagulation cascades	-1.91	1.37e-2	76/85 (89.41%)	THBD;C4BPB;ITGAM;...
Mineral absorption	-2.04	5.13e-3	48/60 (80%)	TRPM6;CLCN2;SLC11A2;...
Ferroptosis	-2.29	0.00e+0	36/41 (87.8%)	GCLM;ACSL1;FTL;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.08uM - 40uM	3H, 6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.08uM - 20uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H